Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03436797 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Efficacy and Safety of AK002 in Subjects With Antihistamine-Resistant Chronic Urticaria
A Phase 2 study, sponsored by Allakos.
- Completed
- Registry status
- Phase 2
- Development phase
- 47
- Enrollment target
NCT03436797 is a Phase 2 study that has completed, run by Allakos. The registered enrollment target is 47 participants.
The verdict
NCT03436797, a Phase 2 study, has completed, sponsored by Allakos.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 47 participants
- Enrollment target
Study Summary
This is a Phase 2a, open-label study to assess the effects of AK002
Interventions
- DRUG AK002
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2018-01-23 |
| Est. Completion | 2020-04-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03436797
The ClinicalTrials.gov registry entry for NCT03436797 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allakos, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AK002 is the first listed.
NCT03436797 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03436797 about?
NCT03436797 is a clinical study titled "A Study to Assess the Efficacy and Safety of AK002 in Subjects With Antihistamine-Resistant Chronic Urticaria". This is a Phase 2a, open-label study to assess the effects of AK002
What is the current status of trial NCT03436797?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 47 participants. The study started on 2018-01-23. Estimated completion is 2020-04-06.
What interventions are being tested in trial NCT03436797?
The interventions under investigation include: AK002 (DRUG).
Who is sponsoring clinical trial NCT03436797?
This trial is sponsored by Allakos, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.